Bombesin in short bowel syndrome.
Short bowel syndrome comprises the sequel of nutrient, fluid, and weight loss that occurs subsequent to greatly reduced functional surface area of the small intestine. The aim of this study is to investigate the trophic and functional effects of bombesin on remaining gut in rats with experimentally induced short bowel syndrome. Thirty-two rats were allocated randomly and experimental short bowel syndrome was induced by 80% bowel resection in all rats. A regular enteral diet and isocaloric elemental enteral nutrition for 12 days were given in the control group and the elemental nutrition group, respectively. In the bombesin group 10 microg/kg subcutaneous bombesin (t.i.d.) for 10 days with regular enteral diet for 12 days was given. In the elemental nutrition and bombesin group the diet consisted of 10 microg/kg subcutaneous bombesin (t.i.d.) for 10 days with isocaloric elemental enteral nutrition for 12 days was given. All rats underwent physical, histological, and biochemical evaluation. Reduction in weight loss, bowel diameter, fecal fat content, and glycemia, increase in cellularity, and d-xylose absorption were observed in all treatment groups. These changes were more evident in the bombesin treatment groups. Increases in serum protein and albumin levels were seen with bombesin treatment with or without elemental diet, whereas reductions in villous height and crypt depth were observed only with bombesin treatment without elemental diet. Serum calcium, iron, and vitamin B(12) levels were not affected with any treatment. It is concluded that bombesin may be a useful trophic agent contributing to increased absorptive capacity and improved biochemical values even in the absence of elemental nutrition.
Uluutku
Ahmet Haldun
AH
Department of General Surgery, Gulhane Military Medical Academy, Haydarpaşa Teaching Hospital, Istanbul, Turkey.
Akin
Mehmet Levhi
ML
Kurt
Yavuz
Y
Yucel
Ergun
E
Cermik
Hakan
H
Avsar
Kadir
K
Celenk
Tuncay
T
D000818:Animals; D001839:Bombesin / Q000627:therapeutic use*; D004750:Enteral Nutrition / Q000379:methods; D006133:Growth Substances / Q000627:therapeutic use*; D008297:Male; D051381:Rats; D020127:Recovery of Function; D012778:Short Bowel Syndrome / Q000178:diet therapy / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome
D006133:Growth Substances; D001839:Bombesin